Austin Miller

28PUBLICATIONS
329CO-AUTHORS
Cancer geneticsPredictive and prognostic markersStochastic analysis and modellingCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Jul 28, 2026
Correction: Oturkar et al. Estrogen Receptor-Beta2 (ERβ2)-Mutant p53-FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC). Cancers 2022, 14, 1120.

|Dec 11, 2025
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.

Robert L Hollis, Austin Miller, Heather A Lankes

|Apr 26, 2025
Improving the Estimation of Prediction Increment Measures in Logistic and Survival Analysis.

Danielle M Enserro, Austin Miller

|Apr 07, 2025
Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial.

Jung-Min Lee, Austin Miller, Peter G Rose

|Oct 03, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.

Jung-Min Lee, Mark F Brady, Austin Miller

|Apr 04, 2024
Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279.

Neil S Horowitz, Wei Deng, Ivy Peterson

Pageof 5

Frequent Collaborators

10 joint publications

Mark H Greene

9 joint publications

Heli Nevanlinna

9 joint publications

Joe Dennis

8 joint publications

Daniel R Barnes